CUP

(redirected from Carcinoma of Unknown Primary)
Category filter:
AcronymDefinition
CUPCalifornia University of Pennsylvania
CUPCuban Peso (ISO currency code)
CUPCambridge University Press
CUPColumbia University Press
CUPConditional Use Permit
CUPCanadian University Press
CUPCancer of Unknown Primary
CUPCommittee of Union and Progress (Turkey)
CUPChina Unionpay (credit card company)
CUPCentro Unico Prenotazioni (Italian: One Centre Bookings)
CUPContents Under Pressure (radio show)
CUPContent Usage Policy (intellectual property; various organizations)
CUPCursor Position
CUPCandidatura d'Unitat Popular (Catalan countries)
CUPCanterbury University Press (New Zealand)
CUPCommission Université Palais (French: University Building Commission)
CUPCommon Unix Printing System
CUPCisco Unified Presence
CUPCompetitive Upgrade
CUPContinuous Upgrade Process
CUPCode Universel des Produits (French: Universal Product Code)
CUPCarcinoma of Unknown Primary
CUPComparable Uncontrolled Price (accounting)
CUPCentral Utility Plant (University of Colorado Denver)
CUPCondom Use Programme (various locations)
CUPChina University of Petroleum (Beijing)
CUPControl Unit Port
CUPClarion University of Pennsylvania
CUPConsumptive Use Permit
CUPCommon Underlying Proficiency
CUPCopper Units of Pressure
CUPConstructor of Useful Parsers
CUPComponent Unit Price (various organizations)
CUPCompassionate Use Program (pharmaceuticals)
CUPCareers Using Physics
CUPCentralized Ultrasound Processing
CUPCommon Undersea Picture
CUPCOMSEC Utility Program
CUPCarupano, Venezuela - Carupano (Airport Code)
CUPCorrosion Under Paint
CUPCommon User Products
CUPConsolidated Utilization Plan
CUPCataloguing Upgrade
CUPCommon User Processor
CUPCommonality Usage Proposal (NASA)
CUPCatalog Update Process
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site.
p16 expression in carcinoma of unknown primary: diagnostic indicator and prognostic marker.
Evaluation of prognostic factors and the role of chemotherapy in unfavourable carcinoma of unknown primary site: A 10-year cohort study.
Carcinoma of unknown primary origin (CUP) is a heterogeneous group of cancers defined by the presence of metastatic disease with no identified primary tumor at presentation.1 It comprised 2 Percent of all cancer in recent year and occurring mostly in 6th and 7th decade of life.2,3 The condition carries a poor prognosis with the average survival from 6 to 9 months.4 An extensive search to find the primary tumor is usually carried out.
(1) Pathologic identification of colonic adenocarcinoma presenting as a mass in the colon does not generally pose diagnostic difficulties; however, approximately 3% to 5% of all new diagnoses of malignancy present as metastases from a carcinoma of unknown primary. (2) The transcription factor SATB2 was recently identified as a potential marker of high specificity in colorectal adenocarcinoma when used in conjunction with marker CK20.
Immunohistology of metastatic carcinoma of unknown primary site," in Diagnostic Immunohistochemistry: Theranostic and Genomic Applications, vol.
There are 12 chapters covering tumors of skin, head and neck, lung and mediastinum; systems of endocrine, digestive, genitourinary, and central nervous system; tumors of breast and female genital organs, hematopoietic and lymphoid, soft tissue and bone, and carcinoma of unknown primary. It is a resource for practitioners and residents alike.
Given this context, routine testing of OPSCC and head and neck lymph nodes harboring squamous cell carcinoma of unknown primary is recommended by an increasing number of organizations such as the College of American Pathologists, the Royal College of Pathologists, and Cancer Care Ontario, (7,14,18) but the optimal techniques for HR-HPV detection have not been fully defined.
Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute.
Full browser ?